Trial Profile
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Axitinib; Talazoparib
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 05 Apr 2023 Planned End Date changed from 1 Mar 2026 to 1 Mar 2027.
- 05 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2025.